Zai Lab (ZLAB) Asset Writedowns and Impairment (2020 - 2026)
Zai Lab (ZLAB) posted quarterly Asset Writedowns and Impairment of $188000.0 for Q1 2026, up 596.3% year-on-year from $27000.0 in Q1 2025, and down 98.35% on a QoQ basis from $11.4 million in Q4 2025.
Zai Lab (ZLAB) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Asset Writedowns and Impairment for 7 consecutive years, with $188000.0 the latest figure, recorded in Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 596.3% year-over-year to $188000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (up 1446.46% YoY) and the FY2025 annual result came in at $12.3 million, up 1407.73% from the prior year.
- Asset Writedowns and Impairment retreated to $188000.0 in Q1 2026 per ZLAB's latest filing, from $11.4 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for ZLAB reached as high as $11.4 million in Q4 2025 and fell as low as -$3000.0 in Q4 2022.
- A 5-year average of $867117.6 and a median of $188000.0 in 2026 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment tumbled 100.31% — and 2025, when it soared 1136800.0%.
- Year by year, Asset Writedowns and Impairment stood at -$3000.0 in 2022, then jumped by 7666.67% to $227000.0 in 2023, then slumped by 99.56% to $1000.0 in 2024, then surged by 1136800.0% to $11.4 million in 2025, then tumbled by 98.35% to $188000.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $188000.0, $11.4 million, and $625000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 11.37 Mn |
| Dec 31, 2025 | 11.37 Mn |
| Sep 30, 2025 | 625,000.00 |
| Sep 30, 2025 | 625,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 58,000.00 |
| Sep 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 719,000.00 |
| Jun 30, 2024 | 719,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Dec 31, 2023 | 227,000.00 |